Megan Kruse, MD, of Cleveland Clinic

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss the clinical benefits reported with neratinib for the treatment of patients with HER2-positive early breast cancer.

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss ongoing research efforts in HER2-positive early breast cancer.

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss optimal management for adverse effects related to neratinib for patients with HER2-positive early breast cancer.

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss unmet needs in the treatment of patients with HER2-positive early breast cancer.

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss how standard-of-care treatment has evolved for patients with HER2-positive early breast cancer.

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss clinical updates to the management of patients with HER2-positive early breast cancer.

Megan Kruse, MD, offers advice to community oncologists treating HER2+ metastatic breast cancer and discusses unmet needs in the treatment landscape.

An overview of agents and treatment strategies currently being investigated in HER2+ metastatic breast cancer.

Megan Kruse, MD, discusses the HER2CLIMB-02 study and the impact it may have on the HER2+ metastatic breast cancer treatment landscape.

Clinical insights on approaches to treating HER2+ metastatic breast cancer with central nervous system involvement.

Megan Kruse, MD, reviews clinical trial data updates from the 2023 ASCO Annual Meeting on HER2+ metastatic breast cancer.

An expert on HER2+ metastatic breast cancer reviews data from the DESTINY-Breast02 and DESTINY-Breast03 trials, which were updated at the 2022 San Antonio Breast Cancer Symposium.

Megan Kruse, MD, discusses the evolving treatment landscape for patients with HER2+ metastatic breast cancer.

Megan Kruse, MD, discusses how socioeconomic disparities and access to health insurance can contribute to poorer overall survival (OS) outcomes in adolescent patients with invasive breast cancer.

Megan Kruse, MD, discusses the real-world effects of the phase 2 MAINTAIN trial on treatment in advanced hormone receptor–positive, HER2-negative breast cancer.

Megan Kruse, MD, discusses the results of a study comparing clinical features and outcomes of pleomorphic vs non-pleomorphic invasive lobular carcinoma.

Megan Kruse, MD, discusses how to converse with patients with breast cancer about implementing biosimilars in treatment.